• 11789 Citations
  • 53 h-Index
1980 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Filter
Review article
2018

Leptomeningeal metastases in non-small-cell lung cancer

Cheng, H. & Perez-Soler, R., Jan 1 2018, In : The Lancet Oncology. 19, 1, p. e43-e55

Research output: Contribution to journalReview article

47 Scopus citations

Mouse models in squamous cell lung cancer: impact for drug discovery

Singh, A. P., Adrianzen Herrera, D., Zhang, Y., Perez-Soler, R. & Cheng, H., Apr 3 2018, In : Expert Opinion on Drug Discovery. 13, 4, p. 347-358 12 p.

Research output: Contribution to journalReview article

2 Scopus citations
2017

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

Hardin, C., Shum, E., Singh, A., Perez-Soler, R. & Cheng, H., May 3 2017, In : Expert Opinion on Pharmacotherapy. 18, 7, p. 701-716 16 p.

Research output: Contribution to journalReview article

14 Scopus citations

Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials

Shum, E., Wang, F., Kim, S., Perez-Soler, R. & Cheng, H., Apr 3 2017, In : Expert Opinion on Investigational Drugs. 26, 4, p. 415-426 12 p.

Research output: Contribution to journalReview article

2 Scopus citations

Pax5 Re-expression in H460 cells treated with the combination of demethylating agent and histone deacetylase inhibitor is associated with the enhancement of P53 binding to Pax5 promoter region

Liang, Y., Zeng, J., Jelicks, L. A., Ma, S., Liu, J., Mei, J., Perez-Soler, R. & Zou, Y., Feb 1 2017, In : Current Cancer Drug Targets. 17, 2, p. 169-176 8 p.

Research output: Contribution to journalReview article

1 Scopus citations
2015

Emerging drugs for squamous cell lung cancer

Cheng, H., Shcherba, M., Kandavelou, K., Liang, Y., Liu, H. & Perez-Soler, R., Mar 1 2015, In : Expert Opinion on Emerging Drugs. 20, 1, p. 149-160 12 p.

Research output: Contribution to journalReview article

12 Scopus citations

Emerging treatment for advanced lung cancer with EGFR mutation

Inal, C., Yilmaz, E., Piperdi, B., Perez-Soler, R. & Cheng, H., Oct 2 2015, In : Expert Opinion on Emerging Drugs. 20, 4, p. 597-612 16 p.

Research output: Contribution to journalReview article

11 Scopus citations
2014

Cell cycle inhibitors for the treatment of NSCLC

Shcherba, M., Liang, Y., Fernandes, D., Perez-Soler, R. & Cheng, H., May 2014, In : Expert Opinion on Pharmacotherapy. 15, 7, p. 991-1004 14 p.

Research output: Contribution to journalReview article

11 Scopus citations

Targeting angiogenesis in squamous non-small cell lung cancer

Piperdi, B., Merla, A. & Perez-Soler, R., Mar 2014, In : Drugs. 74, 4, p. 403-413 11 p.

Research output: Contribution to journalReview article

37 Scopus citations
2012

Mechanisms of resistance to vascular endothelial growth factor blockade

Abdullah, S. E. & Perez-Soler, R., Jul 15 2012, In : Cancer. 118, 14, p. 3455-3467 13 p.

Research output: Contribution to journalReview article

56 Scopus citations
9 Scopus citations
2010

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer

Li, T., Lara, P. N., Mack, P. C., Perez-Soler, R. & Gandara, D. R., Mar 22 2010, In : Current Drug Targets. 11, 1, p. 85-94 10 p.

Research output: Contribution to journalReview article

9 Scopus citations
2009

Individualized therapy in non-small-cell lung cancer: Future versus current clinical practice

Pérez-Soler, R., Aug 2009, In : Oncogene. 28, p. S38-S45

Research output: Contribution to journalReview article

25 Scopus citations

Skin toxicities associated with epidermal growth factor receptor inhibitors

Li, T. & Perez-Soler, R., Apr 1 2009, In : Targeted Oncology. 4, 2, p. 107-119 13 p.

Research output: Contribution to journalReview article

185 Scopus citations
2007

Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

Mitchell, E. P., Perez-Soler, R., Van Cutsem, E. & Lacouture, M. E., Oct 2007, In : Oncology (Williston Park, N.Y.). 21, 11 Suppl 5, p. 4-9 6 p.

Research output: Contribution to journalReview article

40 Scopus citations

EGFR inhibitor-mediated apoptosis in solid tumors

Goel, S., Hidalgo, M. & Perez-Soler, R., Nov 20 2007, In : Journal of Experimental Therapeutics and Oncology. 6, 4, p. 305-320 16 p.

Research output: Contribution to journalReview article

31 Scopus citations
2005

Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?

Peréz-Soler, R. & Saltz, L., Dec 1 2005, In : Journal of Clinical Oncology. 23, 22, p. 5235-5246 12 p.

Research output: Contribution to journalReview article

423 Scopus citations

HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

Pérez-Soler, R., Delord, J. P., Halpern, A., Kelly, K., Krueger, J., Sureda, B. M., Von Pawel, J., Temel, J., Siena, S., Soulières, D., Saltz, L. & Leyden, J., May 1 2005, In : Oncologist. 10, 5, p. 345-356 12 p.

Research output: Contribution to journalReview article

234 Scopus citations
2004

HER1/EGFR Targeting: Refining the Strategy

Pérez-Soler, R., Feb 6 2004, In : Oncologist. 9, 1, p. 58-67 10 p.

Research output: Contribution to journalReview article

96 Scopus citations
2003

Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

Pérez-Soler, R., Nov 2003, In : Oncology (Williston Park, N.Y.). 17, 11 Suppl 12, p. 23-28 6 p.

Research output: Contribution to journalReview article

164 Scopus citations

Erlotinib (Tarceva®): A promising drug targeting epidermal growth factor receptor tyrosine kinase

Bulgaru, A. M., Mani, S., Goel, S. & Perez-Soler, R., Jun 2003, In : Expert Review of Anticancer Therapy. 3, 3, p. 269-279 11 p.

Research output: Contribution to journalReview article

43 Scopus citations

The BCL2-family of protein ligands as cancer drugs: The next generation of therapeutics

Liu, W. J., Bulgaru, A., Haigentz, M., Stein, C. A., Perez-Soler, R. & Mani, S., May 7 2003, In : Current Medicinal Chemistry - Anti-Cancer Agents. 3, 3, p. 217-223 7 p.

Research output: Contribution to journalReview article

39 Scopus citations
2002

Tyrosine kinase inhibitors: a clinical perspective.

Goel, S., Mani, S. & Perez-Soler, R., Jan 2002, In : Current oncology reports. 4, 1, p. 9-19 11 p.

Research output: Contribution to journalReview article

35 Scopus citations
1997

Topotecan in the treatment of non-small cell lung cancer

Perez-Soler, R., Dec 1 1997, In : Seminars in oncology. 24, 6 SUPPL. 20, p. S2034-S2041

Research output: Contribution to journalReview article

11 Scopus citations
1993

Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach

Priebe, W. & Perez-Soler, R., 1993, In : Pharmacology and Therapeutics. 60, 2, p. 215-234 20 p.

Research output: Contribution to journalReview article

60 Scopus citations
1992

Liposomes in the treatment of malignancy: a clinical perspective

Sugarman, S. M. & Perez-Soler, R., May 1992, In : Critical Reviews in Oncology and Hematology. 12, 3, p. 231-242 12 p.

Research output: Contribution to journalReview article

35 Scopus citations
1990

Liposomes as carriers of anticancer agents

Perez-Soler, R., Jan 1 1990, In : Drug News and Perspectives. 3, 5, p. 287-291 5 p.

Research output: Contribution to journalReview article

1 Scopus citations